Emicizumab is a subcutaneous injection preparation indicated for routine prophylactic treatment in adult and pediatric patients. Treatment usually starts with a loading dose, followed by a maintenance phase according to the regimen; the specific dose shall be determined by the doctor based on the individual condition.

1. Recommended Dosage

For subcutaneous injection only.

Loading dose: Subcutaneous injection of 3mg/kg once weekly within the initial 4 weeks.

Maintenance dose (choose one of the following three options): 1.5mg/kg once weekly; 3mg/kg once every two weeks; 6mg/kg once every four weeks.

The selection of the maintenance dose shall be based on the judgment of the healthcare provider and take into account patient compliance.

2. Adjustment of Concomitant Medications

One day before starting emicizumab prophylactic treatment, the prophylactic use of bypassing agents (such as activated prothrombin complex concentrate, aPCC) should be discontinued.

The prophylactic use of factor VIII (FVIII) products can be continued within the first week of emicizumab treatment.

3. Management of Missed Doses

If a dose is missed, it should be administered as soon as possible, and the original dosing schedule should be resumed. Do not inject two doses on the same day to make up for the missed dose.

4. Preparation and Injection

It should be used under the guidance of medical professionals. After receiving training on subcutaneous injection techniques, patients or caregivers may administer the injection themselves (self-injection is not recommended for children under 7 years old).

Before injecting emicizumab, visually inspect the liquid medicine for particles or discoloration (it should be a colorless to slightly yellow solution).

A transfer needle with a filter and an injection needle must be used to withdraw the liquid medicine from the vial.

Do not mix liquid medicines of different concentrations (e.g., 30mg/mL and 150mg/mL) in the same syringe.

The anatomical site should be changed for each injection (e.g., lateral upper arm, thigh, abdominal quadrant), avoiding moles, scars, or skin lesions.

Injections in the lateral upper arm can only be performed by caregivers or medical professionals.

Any unused emicizumab liquid medicine should be discarded.

During use, follow the doctor's instructions and pay attention to monitoring for possible adverse reactions. If abnormal symptoms occur or the therapeutic effect is poor, seek medical attention promptly.